PE20090710A1 - Inhibidores de quinasas simil polo - Google Patents
Inhibidores de quinasas simil poloInfo
- Publication number
- PE20090710A1 PE20090710A1 PE2008001672A PE2008001672A PE20090710A1 PE 20090710 A1 PE20090710 A1 PE 20090710A1 PE 2008001672 A PE2008001672 A PE 2008001672A PE 2008001672 A PE2008001672 A PE 2008001672A PE 20090710 A1 PE20090710 A1 PE 20090710A1
- Authority
- PE
- Peru
- Prior art keywords
- cycloalkyl
- alkyl
- simil
- polo
- cyclopentil
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 CARBONYLOXY Chemical class 0.000 abstract 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028116 Mucosal inflammation Diseases 0.000 abstract 1
- 201000010927 Mucositis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108030005449 Polo kinases Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
REFERIDA A UN COMPUESTO DE FORMULA (I), DONDE W ES N, CF, CH, ENTRE OTROS; Y ES DE PREFERENCIA C; L ESTA AUSENTE O ES LIGADOR QUE PROVEE 1-6 SUSTITUYENTES DE C, O, N, S; R1 ES H, -CN, TIO, ENTRE OTROS; R2 ES H, CARBONILO, ALQUILO C1-C10; R3 ES DE PREFERENCIA H; R4 ES HALO; R5 ES H, HALO, CARBONILOXI, ENTRE OTROS; R6 ES H, CARBONILO, HALOALQUILO C1-C10, ENTRE OTROS; R32 Y R33 SON CADA UNO H, -NO2, -CN, ENTRE OTROS; R34 ES -CONJ34-, NJ34CO-, -NJ34-, ENTRE OTROS; J34 ES H, ALQUILO C1-C4; R35 ES AMINO, ARILO C4-C12, CICLOALQUILO C3-C8, ENTRE OTROS; R36 ES AZALQUILO C1-C4, CICLOALQUILO C3-C8, ENTRE OTROS; R37 ES CICLOALQUILO C3-C8, ALQUILO C1-C4, ENTRE OTROS; n ES 1-4; p, q y r SON CADA UNO DE 0-1. SON COMPUESTOS PREFERIDOS: ACIDO 4-(9-CICLOPENTIL-7,7-DIFLUORO-5-METIL-6-OXO-6,7,8,9-TETRAHIDRO-5H-PIRIMIDO[4,5-b][1,4]DIAZEPIN-2-ILAMINO)-3-METOXIBENZOICO; 4-(9-CICLOPENTIL-7,7-DIFLUORO-5-METIL-6-OXO-6,7,8,9-TETRAHIDRO-5H-PIRIMIDO[4,5-b][1,4]DIAZEPIN-2-ILAMINO)-N-CICLOPROPIL-3-METOXIBENZAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASA SIMIL POLO, UTILES EN EL TRATAMIENTO DEL CANCER, ENFERMEDAD AUTOINMUNE, MUCOSITIS, ENTRE OTROS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97512707P | 2007-09-25 | 2007-09-25 | |
| US3730308P | 2008-03-17 | 2008-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090710A1 true PE20090710A1 (es) | 2009-07-15 |
Family
ID=40219644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001672A PE20090710A1 (es) | 2007-09-25 | 2008-09-25 | Inhibidores de quinasas simil polo |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US8026234B2 (es) |
| EP (3) | EP2205241B1 (es) |
| JP (2) | JP5372939B2 (es) |
| KR (2) | KR101444924B1 (es) |
| CN (2) | CN103122001A (es) |
| AR (1) | AR071729A1 (es) |
| AU (1) | AU2008304417B2 (es) |
| BR (1) | BRPI0817315A2 (es) |
| CA (2) | CA2699607A1 (es) |
| CL (1) | CL2008002852A1 (es) |
| CO (1) | CO6270231A2 (es) |
| CR (1) | CR11370A (es) |
| DO (1) | DOP2010000091A (es) |
| EA (1) | EA019487B1 (es) |
| EC (1) | ECSP10010129A (es) |
| ES (1) | ES2488966T3 (es) |
| GE (1) | GEP20125704B (es) |
| MA (1) | MA31763B1 (es) |
| MX (2) | MX2010003249A (es) |
| MY (1) | MY152283A (es) |
| NZ (1) | NZ584760A (es) |
| PE (1) | PE20090710A1 (es) |
| TN (1) | TN2010000131A1 (es) |
| TW (1) | TWI436769B (es) |
| WO (2) | WO2009042711A1 (es) |
| ZA (1) | ZA201002543B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7622463B2 (en) | 2006-02-14 | 2009-11-24 | Vertex Pharmaceuticals Incorporated | Dihydrodiazepines useful as inhibitors of protein kinases |
| JP5372939B2 (ja) * | 2007-09-25 | 2013-12-18 | 武田薬品工業株式会社 | ポロ様キナーゼ阻害剤 |
| ES2585110T3 (es) * | 2007-09-28 | 2016-10-03 | Cyclacel Limited | Derivados de pirimidina como inhibidores de proteína cinasa |
| WO2009153197A1 (en) * | 2008-06-18 | 2009-12-23 | F. Hoffmann-La Roche Ag | Halo-substituted pyrimidodiazepines as plkl inhibitors |
| EP2414358A1 (en) * | 2009-03-31 | 2012-02-08 | ArQule, Inc. | Substituted tetrahydropyrazolo-pyrido-azepin compounds |
| EP2417127B1 (en) | 2009-04-06 | 2014-02-26 | University Health Network | Kinase inhibitors and method of treating cancer with same |
| BR112012006652A2 (pt) | 2009-09-25 | 2015-09-08 | Vertex Pharma | métodos para preparar os derivados de pirimidina úteis como inibidores de proteína cinase |
| SG179207A1 (en) * | 2009-09-25 | 2012-04-27 | Vertex Pharma | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors |
| SG181908A1 (en) | 2009-12-23 | 2012-08-30 | Elan Pharm Inc | Pteridinones as inhibitors of polo-like kinase |
| EA023173B1 (ru) | 2010-04-06 | 2016-04-29 | Юниверсити Хелс Нетворк | Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью |
| WO2012061342A2 (en) | 2010-11-01 | 2012-05-10 | Arqule, Inc. | Substituted benzo-imidazo-pyrido-diazepine compounds |
| CN103796986B (zh) * | 2011-07-07 | 2015-08-19 | 庵原化学工业株式会社 | 硝基苯化合物的制备方法 |
| WO2013058344A1 (ja) * | 2011-10-21 | 2013-04-25 | 武田薬品工業株式会社 | Plk1阻害剤の効果を予測する方法 |
| CN105764899B (zh) | 2013-10-18 | 2021-06-01 | 大学健康网络 | Plk-4抑制剂的盐和晶型 |
| JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体の使用 |
| CA2936865A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| JP2017526741A (ja) | 2014-08-08 | 2017-09-14 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体およびその使用 |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CA2996974A1 (en) | 2015-09-11 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
| HK1256419A1 (zh) | 2015-09-11 | 2019-09-20 | 达纳-法伯癌症研究所股份有限公司 | 乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途 |
| CN108472295B (zh) | 2015-11-25 | 2022-04-15 | 达纳-法伯癌症研究所股份有限公司 | 二价溴结构域抑制剂及其用途 |
| TWI844006B (zh) * | 2016-05-05 | 2024-06-01 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| EP3959209A4 (en) | 2019-04-24 | 2022-12-28 | University Health Network | S4 CRYSTALLINE FORM OF A PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1H-IMIDAZOL-6-YL )-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE |
| KR20210122163A (ko) | 2020-03-27 | 2021-10-08 | (주) 업테라 | Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물 |
| WO2022145989A1 (ko) * | 2020-12-31 | 2022-07-07 | (주) 업테라 | 선택적 plk1 억제제로서의 피리미도디아제핀 유도체 |
| US20240140962A1 (en) * | 2021-02-08 | 2024-05-02 | Medshine Discovery Inc. | 5,6-dihydrothieno[3,4-h]quinazoline compound |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| CZ2002846A3 (cs) | 1999-09-15 | 2003-02-12 | Warner-Lambert Company | Pteridinony, jako inhibitory kinasy |
| DE60037455T2 (de) | 1999-09-17 | 2008-11-27 | Abbott Gmbh & Co. Kg | Kinaseinhibitoren als arzneimittel |
| KR100955589B1 (ko) | 2001-09-04 | 2010-04-30 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 신규한 디하이드로프테리디논, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| US6806272B2 (en) * | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1630163A1 (de) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2006021548A1 (de) * | 2004-08-27 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| US7622463B2 (en) * | 2006-02-14 | 2009-11-24 | Vertex Pharmaceuticals Incorporated | Dihydrodiazepines useful as inhibitors of protein kinases |
| JP2009537500A (ja) | 2006-05-19 | 2009-10-29 | アストラゼネカ アクチボラグ | 増殖抑制剤としてのジヒドロプテリジン化合物 |
| TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| CA2680757A1 (en) * | 2007-03-22 | 2008-09-25 | F. Hoffmann-La Roche Ag | Substituted pyrimidodiazepines useful as plk1 inhibitors |
| US8461149B2 (en) | 2007-08-15 | 2013-06-11 | Vertex Pharmaceuticals Incorporated | Compounds useful as protein kinase inhibitors |
| JP5372939B2 (ja) | 2007-09-25 | 2013-12-18 | 武田薬品工業株式会社 | ポロ様キナーゼ阻害剤 |
| ES2585110T3 (es) | 2007-09-28 | 2016-10-03 | Cyclacel Limited | Derivados de pirimidina como inhibidores de proteína cinasa |
| WO2009153197A1 (en) | 2008-06-18 | 2009-12-23 | F. Hoffmann-La Roche Ag | Halo-substituted pyrimidodiazepines as plkl inhibitors |
-
2008
- 2008-09-24 JP JP2010526067A patent/JP5372939B2/ja not_active Expired - Fee Related
- 2008-09-24 KR KR1020107009029A patent/KR101444924B1/ko not_active Expired - Fee Related
- 2008-09-24 BR BRPI0817315 patent/BRPI0817315A2/pt not_active IP Right Cessation
- 2008-09-24 US US12/237,306 patent/US8026234B2/en not_active Expired - Fee Related
- 2008-09-24 NZ NZ584760A patent/NZ584760A/en not_active IP Right Cessation
- 2008-09-24 US US12/680,183 patent/US20110201818A1/en not_active Abandoned
- 2008-09-24 WO PCT/US2008/077558 patent/WO2009042711A1/en not_active Ceased
- 2008-09-24 EP EP08834219.1A patent/EP2205241B1/en active Active
- 2008-09-24 CN CN2012105686507A patent/CN103122001A/zh active Pending
- 2008-09-24 MX MX2010003249A patent/MX2010003249A/es active IP Right Grant
- 2008-09-24 KR KR1020147017278A patent/KR20140097440A/ko not_active Ceased
- 2008-09-24 EP EP12189293.9A patent/EP2564850B1/en active Active
- 2008-09-24 MY MYPI20101261 patent/MY152283A/en unknown
- 2008-09-24 CA CA2699607A patent/CA2699607A1/en not_active Abandoned
- 2008-09-24 AU AU2008304417A patent/AU2008304417B2/en not_active Ceased
- 2008-09-24 GE GEAP200811771A patent/GEP20125704B/en unknown
- 2008-09-24 CN CN2008801169537A patent/CN101917995A/zh active Pending
- 2008-09-24 ES ES08834219.1T patent/ES2488966T3/es active Active
- 2008-09-24 EA EA201070395A patent/EA019487B1/ru not_active IP Right Cessation
- 2008-09-25 PE PE2008001672A patent/PE20090710A1/es not_active Application Discontinuation
- 2008-09-25 TW TW097137049A patent/TWI436769B/zh not_active IP Right Cessation
- 2008-09-25 EP EP08833760A patent/EP2197442B1/en not_active Not-in-force
- 2008-09-25 US US12/680,142 patent/US8202990B2/en not_active Expired - Fee Related
- 2008-09-25 MX MX2010003244A patent/MX2010003244A/es active IP Right Grant
- 2008-09-25 CA CA2700295A patent/CA2700295A1/en not_active Abandoned
- 2008-09-25 CL CL2008002852A patent/CL2008002852A1/es unknown
- 2008-09-25 JP JP2010526073A patent/JP2010540464A/ja active Pending
- 2008-09-25 WO PCT/US2008/077746 patent/WO2009042806A1/en not_active Ceased
- 2008-09-25 AR ARP080104179A patent/AR071729A1/es unknown
-
2010
- 2010-03-22 TN TNP2010000131A patent/TN2010000131A1/fr unknown
- 2010-03-25 DO DO2010000091A patent/DOP2010000091A/es unknown
- 2010-04-08 MA MA32753A patent/MA31763B1/fr unknown
- 2010-04-09 CO CO10041197A patent/CO6270231A2/es active IP Right Grant
- 2010-04-12 ZA ZA2010/02543A patent/ZA201002543B/en unknown
- 2010-04-14 CR CR11370A patent/CR11370A/es unknown
- 2010-04-23 EC EC2010010129A patent/ECSP10010129A/es unknown
- 2010-12-07 US US12/962,557 patent/US8318727B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090710A1 (es) | Inhibidores de quinasas simil polo | |
| PE20091408A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| PE20080890A1 (es) | DERIVADOS DE IMIDAZOLONA E IMIDAZOLIDINONA COMO INHIBIDORES DE LA 11b-HSD1 PARA LA DIABETES | |
| PE20071236A1 (es) | Derivados de piperidinilo como moduladores de la actividad del receptor de quimiocina | |
| PE20070189A1 (es) | COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA | |
| PE20050872A1 (es) | Compuestos 5-fenil-tiazol-2-il-amida como inhibidores de la enzima fosfatidilinositol 3-cinasa | |
| PE20081354A1 (es) | Compuestos de azaindolilo como inhibidores de mek | |
| PE20080828A1 (es) | Compuestos y composiciones como inhibidores de la quinasa proteica | |
| PE20060479A1 (es) | Compuestos heteroaril-aril-ureas como inhibidores de la quinasa | |
| PE20060876A1 (es) | Derivados de pirazol como inhibidores de quinasa dependientes de ciclina | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
| TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
| CY1118969T1 (el) | Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak | |
| PE20110944A1 (es) | DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1 | |
| CY1118007T1 (el) | Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων | |
| DE602007009420D1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
| EA200701257A1 (ru) | Пирролопиразолы в качестве сильнодействующих ингибиторов киназы | |
| AR081626A1 (es) | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos | |
| PE20120058A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
| EA200801291A1 (ru) | Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ | |
| PE20100239A1 (es) | Derivados de benzoquinazolina como promotores de la liberacion de hormona paratiroides | |
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| EA201170508A1 (ru) | Производные 1-амино-2-циклобутилэтилбороновой кислоты | |
| PE20080209A1 (es) | Derivados de glicina como inhibidores de prolil hidroxilasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |